Join MitoAction CEO, Kira Mann, Barth Syndrome Foundation CEO, Emily Milligan, and Stealth BioTherapeutics CEO, Reenie …
MitoAction Advocates for Barth Syndrome Community in FDA Listening Session
FOR IMMEDIATE RELEASE
[Boston, MA, April 1, 2024] - MitoAction, a leading nonprofit organization dedicated to …
Expert Series: Ultra-Rare Mitochondrial Diseases: Development Challenges and Opportunities
Join CEO of Stealth Biotherapeutics Reenie McCarthy, and special guest Shelley Bowen, Director of Family Services and …
